Clinical Trial

Optimization of taVNS Intervention Strategies for Refractory Constipation

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 15, 2026 (before its estimated January 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn whether transcutaneous auricular vagus nerve stimulation (taVNS) works to treat refractory constipation in adults. It will also learn about the safety and tolerability of taVNS. The main questions it aims to answer are: Does taVNS improve constipation symptoms, as measured by the change in complete spontaneous bowel movements per week (ΔCSBMs/week) from baseline to post-treatment? What medical problems or side effects do participants have when receiving taVNS? Does taVNS reduce the need for rescue laxatives? Researchers will compare active taVNS to sham taVNS to see if taVNS works to treat refractory constipation. Participants will: Be randomly assigned (double-blind) to receive active taVNS or sham taVNS for 20 days Receive stimulation twice daily, 30 minutes per session, with a 12-hour interval between sessions Receive stimulation at 30 Hz with 200 μs pulse width, delivered to the left cymba conchae Keep a daily diary of bowel habits and symptoms, including CSBMs, and rescue laxative use (bowel movements occurring within 24 hours after rescue laxative use will not be counted as CSBMs)
Trial Details
NCT Number NCT07344402
Lead Sponsor Xijing Hospital of Digestive Diseases
Conditions Refractory Constipation
Enrollment 100 participants
Start Date 2025-09-01
Primary Completion 2026-01-20 (estimated)
Study Completion 2026-01-20 (estimated)
Updated on ClinicalTrials.gov 2026-01-15